Clinical Trial Update: Pembrolizumab in Treating Patients With Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in malignant mesothelioma and related subtypes; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biphasic Mesothelioma
• Epithelioid Mesothelioma
• Malignant Mesothelioma
• Peritoneal Mesothelioma
• Pleural Mesothelioma
• Sarcomatoid Mesothelioma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Chicago | Conditions: Biphasic Mesothelioma, Epithelioid Mesothelioma | Phase 2 | Status: ACTIVE_NOT_RECRUITING